Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results from the CBMTR

Bone Marrow Transplant. 2023 Jan;58(1):106-108. doi: 10.1038/s41409-022-01838-9. Epub 2022 Oct 18.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclophosphamide
  • Fanconi Anemia* / therapy
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Siblings
  • Transplantation Conditioning / methods
  • Unrelated Donors
  • Vidarabine / therapeutic use

Substances

  • fludarabine
  • Vidarabine
  • Cyclophosphamide